drugset
drugset / Trial / NCT05288816

A Study of Single and Multiple Doses of ALXN1210 in Healthy, Adult Japanese Participants

NCT05288816 ↗

Phase 1 Completed 16 enrolled Alexion Pharmaceuticals, Inc.
Non-randomizedParallel-groupOpen-labelBasic science

Summary

This study evaluated the safety and tolerability of single and multiple doses (400 and 800 milligrams \[mg\]) of ALXN1210 following intravenous administration to healthy Japanese participants.

Timeline

Start
2016-04-18
Primary completion
2017-07-05
Completion
2017-07-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Ravulizumab Monoclonal antibody 400 mg Intravenous
Subject Ravulizumab Monoclonal antibody 800 mg Intravenous

Indications

No indication recorded.